Cellzol 2.5mg Tablet

Cellzol 2.5mg Tablet contains Letrozole, a medication used in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women. Letrozole belongs to a class of drugs known as aromatase inhibitors, which work by reducing the production of estrogen in the body, thereby slowing or stopping the growth of hormone-sensitive tumors.

Key Ingredient:

1. Letrozole: Letrozole inhibits the enzyme aromatase, which is responsible for converting androgens (male hormones) into estrogen (female hormone) in the body. By suppressing estrogen production, Letrozole helps deprive hormone-sensitive breast cancer cells of the estrogen they need to grow and proliferate.

Uses:

1. Breast Cancer Treatment: Cellzol 2.5mg Tablet is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy. It is also used for the extended adjuvant treatment of early breast cancer in postmenopausal women who have completed five years of adjuvant tamoxifen therapy.
2. Advanced Breast Cancer: Letrozole is also prescribed for the treatment of advanced breast cancer (metastatic breast cancer) in postmenopausal women who have not responded well to anti-estrogen therapy or who have progressed after receiving tamoxifen therapy.

Administration:

1. Cellzol 2.5mg Tablet is typically taken orally, once a day, with or without food, as directed by a healthcare professional.
2. The dosage and duration of treatment may vary depending on individual medical history, tumor characteristics, and response to therapy. It is important to follow the prescribed regimen provided by a healthcare provider.
3. Swallow the tablet whole with a glass of water; avoid crushing or chewing it unless advised otherwise.

Precautions:

1. Before using Cellzol 2.5mg Tablet, inform your healthcare provider about any allergies, medical conditions, or medications you are taking, especially other hormonal therapies or medications that may affect estrogen levels.
2. Letrozole may cause side effects such as hot flashes, joint pain, fatigue, and bone thinning (osteoporosis). Regular monitoring of bone density and appropriate measures to manage side effects may be necessary during treatment.
3. Letrozole is contraindicated in premenopausal women, pregnant women, and women with a history of hypersensitivity to the drug. It should not be used in these populations.

In Conclusion:

Cellzol 2.5mg Tablet, containing Letrozole, is a hormonal therapy used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. By inhibiting estrogen production, Letrozole helps slow or stop the growth of hormone-sensitive tumors, both in the adjuvant and metastatic settings.